If you need more lookups,
subscriptions start at $34 USD/month.
Sergio Traversa Location
New York, NY, US
Sergio Traversa Work
2012 -now CEO @
2010 -2011 CEO @ Medeor Inc., acquired by Relmada Therapeutics
2007 -2009 Chief Investment Officer @ Ardana Capital
2002 -2006 Pharmaceutical analyst @ Rx Capital Management
2001 -2002 Portfolio Manager, pharmaceutical @ Merlin BioMed Group
2000 -2001 Managing Director, Pharmaceutical Equity Research @ ING Barings
1996 -2000 Pharmaceutical analyst @ Mehta and Isaly
1995 -1996 Country Manager, Southern Europe @
1988 -1993 Hospital Unit Manager, Italy @ Eli Lilly
1986 -1988 Sales representative @ Farmitalia Carlo Erba
Sergio Traversa Education
Leonard Stern School of Business, New York University
MBA (Finance and International Business)
1994-1995
Università degli Studi di Torino
Laurea (Pharmacy)
1979-1985
Liceo Salesiano Valsalice
Sergio Traversa Skills
Equities
Investments
Valuation
Financial Modeling
Private Equity
Hedge Funds
Venture Capital
Portfolio Management
Equity Research
Capital Markets
Due Diligence
Asset Management
Investment Banking
Mergers & Acquisitions
Alternative Investments
Capital
Sales
Microsoft Office
Mergers and Acquisitions
Pharmaceutics
Pharmaceutical Industry
Management
Biotechnology
Cancer
Business Strategy
Pharmacy
Business Analysis
Immunology
Customer Service
Public Speaking
Strategy
Sergio Traversa Summary
Sergio Traversa, based in New York, NY, US, is currently a CEO at Relmada Therapeutics, Inc. Sergio Traversa brings experience from previous roles at Medeor Inc., acquired by Relmada Therapeutics, Ardana Capital, Rx Capital Management and Merlin BioMed Group. Sergio Traversa holds a 1994 - 1995 MBA in Finance and International Business @ Leonard Stern School of Business, New York University. With a robust skill set that includes Equities, Investments, Valuation, Financial Modeling, Private Equity and more. Sergio Traversa has 2 emails and 2 mobile phone numbers on RocketReach.
Looking for a different Sergio Traversa?
Find contact details for 700 million professionals.